Physician profile
John C Goetzinger
NPI 1174979942
$17,727.53
in general payments reported to CMS, 2019-2025
27 companies · $4,515 in 2025
The $4,515 reported for 2025 was more than what 84% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $233 · 2021: $876 · 2022: $1,805 · 2023: $2,304 · 2024: $7,994 · 2025: $4,515.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,370 · Consulting Fee: $6,080 · Travel and Lodging: $1,228 · Education: $135.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,370.48 |
| Consulting Fee | $6,080.00 |
| Travel and Lodging | $1,227.52 |
| Education | $134.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $6,127.95 | 2022-2025 | Bimzelx, Cimzia |
| Abbvie INC. | $2,744.11 | 2020-2025 | |
| Progentec Diagnostics, INC. | $2,400.00 | 2025 | |
| Amgen INC. | $1,142.96 | 2021-2025 | Enbrel, Tavneos, Evenity |
| Janssen Biotech, INC. | $1,108.08 | 2020-2025 | Tremfya, Simponi Aria, Remicade |
| Astrazeneca Pharmaceuticals LP | $898.31 | 2021-2025 | Saphnelo |
| Novartis Pharmaceuticals Corporation | $441.16 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $394.91 | 2021-2025 | Orencia |
| Glaxosmithkline, LLC. | $352.02 | 2020-2025 | Benlysta |
| Genzyme Corporation | $338.92 | 2023-2025 | |
| Lilly USA, LLC | $314.52 | 2021-2024 | Taltz |
| Genentech USA, INC. | $299.55 | 2021-2024 | Actemra |
| Horizon Therapeutics Plc | $245.47 | 2022-2023 | Krystexxa |
| Janssen Scientific Affairs, LLC | $203.25 | 2021-2022 | |
| Sandoz INC. | $137.59 | 2023-2025 | Hyrimoz |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $108.39 | 2023-2025 | Ofev, Cyltezo |
| Aurinia Pharma U.S., INC. | $69.63 | 2024-2025 | Lupkynis |
| Pfizer INC. | $64.90 | 2022-2025 | |
| Dexcom, INC. | $59.24 | 2022-2023 | Dexcom G6 Transmitter |
| Alexion Pharmaceuticals, INC. | $52.05 | 2024-2025 | Strensiq |
| Fresenius Kabi USA, LLC | $51.15 | 2023-2025 | Idacio |
| Ani Pharmaceuticals, INC. | $49.09 | 2022 | |
| Mallinckrodt Hospital Products INC. | $38.86 | 2024 | Acthar |
| Actelion Pharmaceuticals US, INC. | $36.17 | 2022 | |
| Organon LLC | $25.67 | 2023 | Hadlima |
| Mylan Institutional INC. | $23.58 | 2023 | Hulio |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Goetzinger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.